Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: A randomized study in Bihar, India

American Journal of Tropical Medicine and Hygiene

Volumn 84, Issue 6, 2011, Pages 892-900

  Sundar, Shyam ^b   Sinha, Prabhat K ^a   Dixon, Susan A ^c   Buckley, Renata ^c   Miller, Ann K ^d   Mohamed, Khadeeja ^c   Al Banna, Mahir ^d  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; FUNGICIN; SITAMAQUINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILL; CLINICAL STUDY; CONTROLLED STUDY; CONVALESCENCE; CREATININE URINE LEVEL; DIARRHEA; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; FEVER; FOOD INTAKE; GASTRITIS; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; URINARY TRACT INFECTION; URTICARIA; VISCERAL LEISHMANIASIS; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMINOQUINOLINES; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; AREA UNDER CURVE; COHORT STUDIES; CROSS-OVER STUDIES; FASTING; FEMALE; FOOD; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79958748637     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.10-0409     Document Type: Article

References (26)

1. World Health Organization, 2005. Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region (2005-2015). New Delhi: World Health Organization. Available at : http://www.searo.who.int/LinkFiles/ Kala-azar-VBC-85- Rev-1.pdf. Accessed April 27, 2010.
2. Singh SP, Reddy DC, Rai M, Sundar S, 2006. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 11: 899-905. (Pubitemid 43846450)
3. Joshi A, Narain JP, Prasittisuk C, Bhatia R, Hashim G, Jorge A, Banjara M, Kroeger A, 2008. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 45: 105-111.
4. Thakur CP, Narayan S, Ranjan A, 2004. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 120: 166-172. (Pubitemid 39406044)
5. Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK, 2005. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India 18: 131-133. (Pubitemid 41158105)
6. Croft SL, Sundar S, Fairlamb AH, 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126. (Pubitemid 43157649)
7. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 2571-2581. (Pubitemid 46961002)
8. Deray G, 2002. Amphotericin B nephrotoxicity. J Antimicrob Chemother 49 (Suppl 1) : 37-41.
9. Meheus F, Boelaert M, Baltussen R, Sundar S, 2006. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health 11: 1715-1724. (Pubitemid 44624375)
10. Barratt G, Legrand P, 2005. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis. Curr Opin Infect Dis 18: 527-530. (Pubitemid 41634766)
11. More B, Bhatt H, Kukreja V, Ainapure S, 2003. Miltefosine: great expectations against visceral leishmaniasis. J Postgrad Med 49: 101-103. (Pubitemid 36758286)
12. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW, 1999. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 93: 589-597. (Pubitemid 29438129)
13. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fisher C, Voss A, Berman J, 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341: 1795-1800.
14. Prasad R, Kumar R, Jaiswal BP, Singh UK, 2004. Miltefosine: an oral drug for visceral leishmaniasis. Indian J Pediatr 71: 143-144. (Pubitemid 38325649)
15. Bhattacharya SK, Sur D, Sinha PK, Karbwang J, 2006. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible and operationally achievable. Indian J Med Res 123: 195-196. (Pubitemid 43905562)
16. Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J, 2005. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 73: 1005-1011. (Pubitemid 43038244)
17. Wasunna MK, Rashid JR, Mbui J, Kirigi G, Kinoti D, Lodenyo H, Felton JM, Sabin AJ, Albert MJ, Horton J, 2005. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 73: 871-876. (Pubitemid 41688461)
18. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, Sanchez J, Schuster B, Grogl M, 2001. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 65: 685-689. (Pubitemid 34049456)
19. Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR, Wasunna KM, Were JB, Kasili SK, Mbugua JM, Kirigi G, Shaefer KU, Oster CN, Fleckenstein LL, Berman JD, Brewer TG, Roberts CR, Johnson AJ, Schuster BG, 1994. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 19: 1034-1039. (Pubitemid 24380014)
20. Yeates C, 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr Opin Investig Drugs 3: 1446-1452.
21. National Cancer Institute, 2003. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD : National Cancer Institute. Available at : http://ctep.cancer.gov/reporting/ ctc.html. Accessed April 27, 2010.
22. National Institute of Allergy and Infectious Diseases (NIAID), US, Division of Microbiology and Infectious Diseases, 2001. Adult Toxicity Table.
23. Chulay JD, Bryceson AD, 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475-479. (Pubitemid 13101435)
24. Steinijans VW, Diletti E, 1983. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 24: 127-136. (Pubitemid 13181796)
25. Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW, 2007. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 45: 556-561. (Pubitemid 47328634)
26. Thakur CP, Narayan S, 2004. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Ann Trop Med Parasitol 98: 129-138. (Pubitemid 38388881)